Business Context and Reporting Period
MIRA Pharmaceuticals, Inc. (MIRA), a preclinical-stage pharmaceutical company, filed this Form 8-K on November 19, 2024. The filing reports the selection of The Centre for Human Drug Research (CHDR) in Leiden, The Netherlands, as the clinical trial site for Ketamir-2, a novel oral ketamine analog.
Key Financial Metrics
This filing is a Current Report (Item 8.01 Other Events) and does not contain financial statements. The text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the advancement of the Ketamir-2 development program:
- Site Selection: CHDR selected for the Phase I/IIa clinical trial.
- Technology Integration: The trial will utilize CHDR's proprietary PainCart technology to measure pain response and assess early efficacy in healthy subjects during Phase I.
- Timeline: Recruitment begins Q1 2025; Phase I safety/efficacy results expected H2 2025; Phase IIa (diabetic neuropathy) starts Q4 2025 with results anticipated H1 2026.
Outlook, Risks, and Management Commentary
Management highlights the unique capability of the PainCart technology to gain insights into pain management potential earlier in the clinical process. The filing includes a standard cautionary note regarding forward-looking statements, noting that actual results may differ materially due to risks described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. No specific financial guidance or unusual items were disclosed in this text.
Investor Verification Checklist
- Verify the status of the Investigational New Drug (IND) application for Ketamir-2.
- Confirm the specific terms of the agreement with CHDR regarding the use of PainCart technology.
- Review the Company's cash runway and capital requirements to fund the upcoming Phase I/IIa trials starting in 2025.
- Monitor the Q1 2025 recruitment timeline for potential delays.